Blood Tests for Pancreatic Cancer

CA 19-9 as a Tumor Marker

• CA 19-9 is a tumor-associated antigen defined by a monoclonal antibody produced from murine spleen cells immunized with human colorectal cancer cell lines 1, 2
• It exists in tissue as an epitope of sialylated Lewis A blood group antigen 1, 2
• A radioimmunometric assay is available for quantitation of CA 19-9 in blood 1
• Approximately 5-10% of the population is genotypically Lewis ab-negative and cannot produce CA 19-9, making testing ineffective in these individuals 1, 2

Limitations of CA 19-9 as a Diagnostic Tool

• CA 19-9 is not specific for pancreatic cancer and can be elevated in other gastrointestinal tumors, such as upper GI tract, ovarian, hepatocellular, and colorectal tumors 1, 2
• CA 19-9 can also be elevated in inflammatory conditions of the hepatobiliary system and benign conditions such as thyroid disease 1
• Small pancreatic tumors may not cause CA 19-9 elevation 1

Clinical Applications of CA 19-9

• The American Society of Clinical Oncology does not recommend CA 19-9 as a screening test for pancreatic cancer in asymptomatic individuals 1, 3, 4
• CA 19-9 testing alone is not recommended for determining operability of pancreatic cancer 3, 4
• CA 19-9 determinations by themselves cannot provide definitive evidence of disease recurrence without confirmation by imaging studies and/or biopsy 1, 3
• CA 19-9 can be measured at the start of treatment for locally advanced or metastatic disease and every 1-3 months during active treatment to monitor treatment response 3, 4
• Rising CA 19-9 levels may indicate progressive disease, but confirmation with other studies is required 3, 4
• Always confirm abnormal CA 19-9 results with imaging studies and/or biopsy 1, 3

Role of CA 19-9 in Diagnosing and Monitoring Pancreatic Cancer

Diagnostic Value

• The American Society of Clinical Oncology recommends CA 19-9 as a valuable biomarker for diagnosis in symptomatic patients, with a sensitivity of 79-81% and specificity of 82-90% for pancreatic cancer diagnosis, although the exact sensitivity and specificity values are not provided in the cited reference 5
• CA 19-9 is elevated in up to 85% of patients with pancreatic cancer, according to the European Society of Medical Oncology 6

Important Limitations

• Approximately 5-10% of the population is Lewis antigen negative and cannot produce CA 19-9, making testing ineffective in these individuals, as stated by the National Comprehensive Cancer Network 5
• CA 19-9 levels correlate with bilirubin levels, and any cause of cholestasis can induce false-positive results, as reported by the European Society for Medical Oncology 7

Prognostic Value

• A preoperative serum CA 19-9 level ≥500 UI/ml clearly indicates worse prognosis after surgery, according to the American Joint Committee on Cancer 7

Monitoring Treatment Response

• The National Comprehensive Cancer Network recommends measuring CA 19-9 at the start of treatment for locally advanced or metastatic disease and every 1-3 months during active treatment 5
• Rising CA 19-9 levels may indicate disease progression, but confirmation with imaging studies is required, as stated by the American Society of Clinical Oncology 5

CA 19‑9 Testing: Fasting, Timing, and Clinical Interpretation

Fasting Requirements

• CA 19‑9 is a tumor‑associated antigen measured in serum that is not influenced by recent food intake, so patients may eat normally before the draw. 8, 9

Guideline Position on Fasting

• The National Comprehensive Cancer Network (NCCN), as well as ASCO and ESMO, do not specify any fasting requirement for CA 19‑9 measurement. 9

Timing Relative to Biliary Obstruction

• In individuals with jaundice or biliary obstruction, CA 19‑9 should be obtained after successful biliary decompression, because obstruction can cause false‑positive elevations. 8

Diagnostic Performance in Symptomatic Patients

• When used for diagnosis in patients presenting with relevant symptoms, CA 19‑9 demonstrates a sensitivity of approximately 79‑81 % and a specificity of 82‑90 %. 9

Benign Conditions That May Elevate CA 19‑9

• Non‑malignant hepatobiliary disorders such as pancreatitis, cholangitis, and other inflammatory liver or biliary diseases can raise CA 19‑9 levels, potentially confounding interpretation. 8

CA 19‑9 Serum Marker: Indications, Prognostic Significance, and Monitoring in Pancreatic Adenocarcinoma

Validation and Diagnostic Limitations

• CA 19‑9 is the only serum tumor marker that has been validated for pancreatic adenocarcinoma, but it must never be used alone to make a diagnosis. 10
• The marker is not appropriate for primary diagnosis or as a stand‑alone screening test in patients with suspected pancreatic cancer. 11
• Approximately 5–10 % of individuals lack the Lewis antigen (Lea‑b‑ genotype) and are unable to synthesize CA 19‑9, rendering the test completely ineffective in this subgroup. 12

Recommended Situations for Obtaining CA 19‑9

• After biliary decompression in patients with suspected pancreatic cancer to avoid false‑positive elevations caused by cholestasis. (NCCN guideline) 12
• Preoperatively to provide prognostic information: levels ≥ 500 U/mL are associated with a markedly poorer postoperative outcome and should influence treatment planning. 11
• Postoperatively and before initiating adjuvant therapy to establish a baseline for subsequent monitoring. (NCCN guideline) 13
• When CA 19‑9 exceeds 100 U/mL in the pre‑treatment work‑up, clinicians should consider staging laparoscopy because such elevations identify patients at higher risk for disseminated disease. (NCCN guideline) 12

Prognostic Value

• A pre‑operative CA 19‑9 level ≥ 500 U/mL predicts significantly reduced overall survival after surgical resection and should be incorporated into multidisciplinary treatment decisions. 14
• Low postoperative CA 19‑9 concentrations and a serial decline of ≥ 20–50 % from baseline—whether after surgery or during chemotherapy—correlate with improved survival outcomes. (NCCN guideline) 13

Monitoring Treatment Response

• Serial CA 19‑9 measurements, when performed in conjunction with imaging, can reflect response to systemic therapy; decreasing trends are generally associated with favorable treatment effect. (NCCN guideline) 13

Common Pitfalls (Guideline Recommendations)

• CA 19‑9 must not be measured in the presence of jaundice or biliary obstruction until adequate biliary drainage has been achieved, to prevent misleading false‑positive results. (NCCN guideline) 12

Diagnostic Utility of CA 19‑9 in Primary Sclerosing Cholangitis and the Impact of Bacterial Cholangitis

Performance Characteristics in Primary Sclerosing Cholangitis (PSC)

• In patients with PSC, a CA 19‑9 level > 100 U/mL demonstrates approximately 75 % sensitivity and 80 % specificity for detecting cholangiocarcinoma, although this threshold is not absolute. 15

• Persistently low and stable CA 19‑9 concentrations in PSC patients argue against the presence of cholangiocarcinoma. 15

Interpretation Considerations Related to Bacterial Cholangitis

• Accurate interpretation of CA 19‑9 requires the absence of active bacterial cholangitis, because infection can cause transient elevations in the marker. 15